Jean-Pierre Sommadossi, Atea CEO
October 19, 2021 08:28 AM EDTUpdated 10:38 AM
R&D
Coronavirus

Roche-Atea’s Covid-19 pill fails mid-stage tri­al, cloud­ing fu­ture for close­ly watched pro­gram

Jason Mast

Editor

When Mer­ck an­nounced this month that its Covid-19 pill cut new­ly di­ag­nosed pa­tients’ risk of be­ing hos­pi­tal­ized by 50%, re­searchers and an­a­lysts hoped that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times